Who is sponsoring NCT00126074?

NCT00126074 is sponsored by Solvay Pharmaceuticals.

What drugs are being tested in NCT00126074?

Interventions in NCT00126074: Tedisamil sesquifumarate.

What condition does NCT00126074 study?

NCT00126074 studies Atrial Fibrillation, Atrial Flutter.

Is NCT00126074 still recruiting?

NCT00126074 is currently completed. Last updated 15 January 2015.

Last reviewed 2015-01-15 · How we verify

NCT00126074

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation or Flutter

Completed Phase 3 Last updated 15 January 2015

What this trial tests

Phase 3 trial testing Tedisamil sesquifumarate in Atrial Fibrillation. Completed in 1 March 2006.

Timeline

1 October 2004

Primary endpoint
1 March 2006

1 March 2006

Quick facts

Lead sponsor	Solvay Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 October 2004
Primary completion	1 March 2006
Estimated completion	1 March 2006
Sites	26 locations across United States, Bulgaria, Germany, Hungary, Italy, Poland

Drugs / interventions tested

Tedisamil sesquifumarate — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Atrial Flutter — all drugs for Atrial Flutter →

Sponsor

Solvay Pharmaceuticals — full company profile →

Who can join

18 and older, female only, with Atrial Fibrillation or Atrial Flutter. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00126074 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Solvay Pharmaceuticals
Last refreshed: 15 January 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00126074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing